- Stem cells faulty in Duchenne muscular dystrophy, Stanford researchers find
- ‘Genome editing’ could correct genetic mutations for future generations
- University of Toronto cell biologists discover on-off switch for key stem cell gene
- Patient’s own stem cells could clear a cloudy cornea, Pitt team says
- Discovery links shift in metabolism to stem cell renewal
- Immunotherapy shows clinical benefit in relapsed transplant recipients
- Turning biological cells to stone improves cancer and stem cell research
- Stem cell transplant without radiation or chemotherapy pre-treatment shows promise
Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the Stanford University School of Medicine have found that the fault may lie at least partly in the stem cells that surround the muscle fibers.
Scientists at Indiana University and colleagues at Stanford and the University of Texas have demonstrated a technique for “editing” the genome in sperm-producing adult stem cells, a result with powerful potential for basic research and for gene therapy.
Consider the relationship between an air traffic controller and a pilot. The pilot gets the passengers to their destination, but the air traffic controller decides when the plane can take off and when it must wait. The same relationship plays out at the cellular level in animals, including humans. A region of an animal’s genome – the controller – directs when a particular gene – the pilot – can perform its prescribed function.
Treating the potentially blinding haze of a scar on the cornea might be as straightforward as growing stem cells from a tiny biopsy of the patient’s undamaged eye and then placing them on the injury site, according to mouse model experiments conducted by researchers at the University of Pittsburgh School of Medicine. The findings, published today in Science Translational Medicine, could one day rescue vision for millions of people worldwide and decrease the need for corneal transplants.
Stem cells in early embryos have unlimited potential; they can become any type of cell, and researchers hope to one day harness this rejuvenating power to heal disease and injury. To do so, they must, among other things, figure out how to reliably arrest stem cells in a Peter Pan-like state of indefinite youth and potential. It’s clear the right environment can help accomplish this, acting as a sort of Neverland for stem cells. Only now are scientists beginning to understand how.
A multicenter phase 1 trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation, according to investigators from Dana-Farber Cancer Institute, who developed and lead the study.